Business Wire

QUIT-LIKE-SWEDEN

Share
Quit Like Sweden Urges Progressive Tobacco Control to Save Millions of Lives on World No Tobacco Day

Millions of lives could be saved with a more progressive approach to tobacco control measures, says a new platform committed to encouraging countries to follow the Swedish Experience and become ‘smoke-free’. As the world gears up to observe World No Tobacco Day (WNTD) on May 31, Quit Like Sweden, launched earlier this year in Brazil, is calling for proven strategies to enhance the global fight against smoking.

Traditionally, WNTD has been marked exclusively by calls for the complete abandonment of smoking. However, Quit Like Sweden argues that it's time for policymakers, regulators, governments, the media, and the general public to engage in a meaningful discussion about the strategies that do reduce the devastating impacts of smoking and smoking-related illnesses.

Suely Castro, Founder of Quit Like Sweden, emphasized the need for a new approach, citing the Swedish Experience and remarkable progress in tobacco control.

"Each World No Tobacco Day, the international community argues that a world without cigarettes is the ultimate aim. But this World No Tobacco Day, instead of discussing what could be possible, it’s time to look at what is already being done by the only country that is close to quitting smoking: Sweden," said Suely Castro.

While Sweden has rigorously adopted smoking cessation and prevention measures, it has also enabled smokers to choose safer alternatives. This approach, based on what Ms Castro calls the three A's – which stand for the Accessibility, Acceptability, and Affordability of safer alternatives – has resulted in millions of Swedes choosing to leave cigarettes behind and switch to safer alternatives.

"In Sweden, one in four adults uses nicotine every day. While this is the same level as the rest of Europe, Sweden’s incidence of cancer is 41% lower, and smoking-related deaths in Sweden are less than half of smoking-related deaths in 24 of the other 26 EU countries”, Castro said.

“This is the case within European countries, which have similar regulations to those of Sweden, although not its comprehensive approach to eradicating smoking. Just imagine what the global impact of the full Swedish Experience could be.”

“We have the ability to save millions of lives just by replicating a model that has already worked so well for Sweden,” she said. "And there’s no better time to start that conversation than now.”

Background

Quit Like Sweden is a not-for-profit platform with the aim to encourage countries to take action to replicate the Swedish Experience in a comprehensive strategy that also includes measures and programmes focused on smoking cessation and prevention, and enabling people who smoke to choose alternatives instead.

We don’t advocate for the removal of measures and programmes that contribute to smoking cessation or prevention, and instead appeal to all policymakers in all countries, intergovernmental and non-governmental organizations to complement those measures and programmes.

Sweden Statistics

As a result of Sweden’s progressive tobacco control measures:

  1. Sweden is the only country in the world to officially be ‘smoke-free’, when its smoking prevalence falls below 5% later this year.
  2. Across Europe, the smoking rate is 5 times higher than Sweden’s.
  3. 24 of the 27 EU countries have a tobacco-related mortality rate at least twice as high as Sweden’s.
  4. Sweden’s incidence of cancer is 41% lower than the rest of Europe’s, which means 38% lower levels of total cancer deaths.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529797728/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye